News|Articles|November 2, 2018

Pharmaceutical Technology

  • Pharmaceutical Technology-11-02-2018
  • Volume 42
  • Issue 11

Uniformity of Dosage Units, Part 1: Acceptance Value

This paper describes how the concept of acceptance value can be redefined to remove bias and more closely reflect quality targets.

The method currently used to ensure the uniformity of dosage units can result in bias and may allow batches of inferior quality to be released. The bias can result in fluctuated conclusions, especially when guidance established by the American Society for Testing and Materials’ (ASTM) E2810 standard guide is followed. Studies have found lack of correlation between AV and probability (ASTM E2810) computed using validation data. This inconsistency is caused by the conditional determination criteria that are used to determine the reference value. The concept of acceptance value must be redefined to remove bias and more closely reflect quality targets. This paper describes how this can be done.

Please click

here

for a PDF of the article.

Peer-Reviewed

Submitted: June 12, 2018
Accepted: July 20, 2018

About the author

Pramote Cholayudth is validation consultant to Biolab Co., Ltd. in Thailand. He is a guest speaker on process validation to industrial pharmaceutical scientists organized by local regulatory authorities. He is the founder and manager of PM Consult and can be contacted via cpramote2000@yahoo.com.

Article Details

Pharmaceutical Technology
Vol. 42, No. 11
November 2018
Pages: 30–39, 45

Citation

When referring to this article, please cite it as P. Cholayudth, “Uniformity of Dosage Units, Part 1: Acceptance Value” Pharmaceutical Technology 42 (11) 2018.

 


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.